Jazz gets FDA OK for recombinant lymphoma/leukemia med

 Approval under U.S. FDA's Real-Time Oncology Review program represents an important therapeutic advance for pediatric and adult patients who develop hypersensitivity to E. coli-derived asparaginase treatments

Rylaze is expected to become commercially available in the U.S. in mid-July

Company to host investor webcast in July; details to follow

https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-us-fda-approval-of-rylaze-asparaginase-erwinia-chrysanthemi-recombinant-rywn-for-the-treatment-of-acute-lymphoblastic-leukemia-or-lymphoblastic-lymphoma-301323782.html